UTMB Initiates Enrollment for Brain Tumor Imaging Trial Using Novel Agent

The University of Texas Medical Branch (UTMB) has commenced recruitment for a U.S. Phase 2 clinical trial, examining a promising imaging compound designed to enhance the visualization of brain tumors during surgical procedures. This investigational agent, FG001, developed by FluoGuide A/S in Denmark, aims to assist neurosurgeons in delineating the borders between tumors and healthy brain tissue in patients with newly diagnosed high-grade gliomas.

High-grade gliomas, classified as grade 3 or grade 4 tumors by the World Health Organization, are aggressive brain malignancies that pose significant surgical challenges due to their complex and invasive nature. Dr Pablo Valdes, a distinguished expert in Neurosurgical Oncology at UTMB, is at the helm of this study. The U.S. Food and Drug Administration (FDA) has granted FG001 a Fast Track designation, underscoring its potential to address a critical gap in the treatment landscape for these tumors.

Dr Valdes stated, "High-grade glioma is a devastating disease, and surgeons need better tools to identify and remove cancerous tissue while preserving healthy brain tissue. FG001 has the potential to improve intraoperative tumor detection, and I am excited to evaluate this new imaging agent to support more precise surgery for patients with high-grade glioma."

The core challenge in brain tumor surgeries is distinguishing tumor margins from adjacent normal brain tissue. FG001 aims to facilitate this by binding to cancerous cells, allowing them to fluoresce under near-infrared imaging during operations. This fluorescence provides surgeons with a real-time, visual guide to better identify and excise tumor tissue while minimizing harm to healthy brain regions.

During the trial, patients are administered a single intravenous dose of FG001 approximately 12 to 19 hours prior to surgery. Using specialized imaging equipment, surgeons are able to visually discriminate tumor tissue, thus enhancing surgical precision. The trial will assess FG001's effectiveness in differentiating tumor from non-tumor tissue and its contribution to successful tumor resection.

Postoperative MRI scans will be utilized within 48 hours to evaluate the extent of tumor removal. Participants will be monitored for six months post-surgery to observe safety, neurological outcomes, functional ability, and quality of life.

This trial is significant for advancing fluorescence-guided surgical techniques—areas of research that Dr Valdes is renowned for. The investigational agent FG001 aligns with his work in developing innovative strategies to improve surgical outcomes for brain tumor patients. The study is multicentric and open-label, involving multiple research facilities where both clinicians and participants are aware of FG001's administration. In addition to gliomas, FluoGuide is exploring FG001’s potential applications in other cancers. According to Valdes, "Ultimately, this is about giving patients the best possible outcome. The more clearly we can distinguish tumor from healthy brain during surgery, the better equipped we are to remove the tumor safely and precisely. Our hope is that advanced tools will provide that critical information when surgeons need it most."